Loading...
Market
Which company will have the largest market share of ADHD medications in the U.S. by December 31, 2024?
2
Resolution / Starting Odds
Takeda Pharmaceutical • 25%
Teva Pharmaceutical • 25%
Eli Lilly • 25%
Other • 25%
Market share reports from industry analysts and market research firms
Story
DEA Increases Vyvanse Production Limit by 24% to Address ADHD Drug Shortage
Sep 4, 2024, 11:15 AM
The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical's ADHD drug Vyvanse and its generic versions by about 24% to address the ongoing shortage of the medication in the United States. This decision aims to mitigate the impact of the current drug shortage affecting ADHD treatment. The US is allowing 24% more production of Vyvanse and its generic rivals to address treatment shortages.
View original story
Similar markets
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
Roche's CT-996 has the largest market share • 25%
Novo Nordisk has the largest market share • 25%
Eli Lilly has the largest market share • 25%
Other companies have the largest market share • 25%
Kisunla™ • 33%
Leqembi • 33%
Other/new drugs • 33%
MariTide leads market share • 25%
Eli Lilly leads market share • 25%
Novo Nordisk leads market share • 25%
Market share is evenly distributed • 25%
DDL-920 • 25%
Aduhelm • 25%
Leqembi • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Sanofi • 25%
Other • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Viking Therapeutics • 25%
Other • 25%
Eli Lilly • 25%
Novo Nordisk • 25%
Pfizer • 25%
Other • 25%
High-dose psilocybin • 25%
Escitalopram • 25%
Sertraline • 25%
Other • 25%
Company A • 25%
Company B • 25%
Company C • 25%
Other • 25%
AbbVie • 25%
Bristol Myers Squibb • 25%
Another major pharmaceutical company • 25%
No new approvals • 25%
Novo Nordisk • 25%
Eli Lilly • 25%
Pfizer • 25%
Other • 25%